News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
745,697 Results
Type
Article (44105)
Company Profile (468)
Press Release (701106)
Multimedia
Podcasts (140)
Webinars (23)
Section
Business (209481)
Career Advice (2046)
Deals (36203)
Drug Delivery (137)
Drug Development (84098)
Employer Resources (174)
FDA (16780)
Job Trends (15220)
News (354563)
Policy (33305)
Tag
2027 BioCapital Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2683)
Accelerated approval (48)
Adcomms (30)
Allergies (174)
Alliances (51115)
ALS (213)
Alzheimer's disease (1834)
Antibody-drug conjugate (ADC) (458)
Approvals (17116)
Artificial intelligence (672)
Autoimmune disease (268)
Automation (52)
Bankruptcy (374)
Best Places to Work (11840)
BIOSECURE Act (20)
Biosimilars (221)
Biotechnology (330)
Bladder cancer (189)
Brain cancer (74)
Breast cancer (748)
Cancer (5832)
Cardiovascular disease (477)
Career advice (1737)
Career pathing (43)
CAR-T (331)
CDC (56)
Celiac Disease (3)
Cell therapy (894)
Cervical cancer (46)
Clinical research (72504)
Collaboration (2124)
Company closure (5)
Compensation (1371)
Complete response letters (88)
COVID-19 (2797)
CRISPR (113)
C-suite (1116)
Cystic fibrosis (159)
Data (7672)
Decentralized trials (3)
Denatured (44)
Depression (169)
Dermatology (79)
Diabetes (582)
Diagnostics (6959)
Digital health (54)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (330)
Drug pricing (211)
Drug shortages (32)
Duchenne muscular dystrophy (293)
Earnings (92769)
Editorial (68)
Employer branding (21)
Employer resources (153)
Events (122865)
Executive appointments (1098)
FDA (20456)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (15)
Frontotemporal dementia (35)
Funding (1756)
Gene editing (246)
Generative AI (56)
Gene therapy (747)
GLP-1 (1088)
Government (4820)
Grass and pollen (6)
Guidances (404)
Healthcare (19307)
HIV (80)
Huntington's disease (57)
IgA nephropathy (97)
Immunology and inflammation (312)
Immuno-oncology (93)
Indications (177)
Infectious disease (3138)
Inflammatory bowel disease (218)
Inflation Reduction Act (17)
Influenza (138)
Intellectual property (291)
Interviews (318)
IPO (16950)
IRA (53)
Job creations (3717)
Job search strategy (1442)
JPM (67)
Kidney cancer (18)
Labor market (96)
Layoffs (593)
Leadership (39)
Legal (8032)
Liver cancer (101)
Longevity (33)
Lung cancer (772)
Lymphoma (427)
Machine learning (60)
Management (59)
Manufacturing (1019)
MASH (187)
Medical device (14058)
Medtech (14159)
Mergers & acquisitions (20476)
Metabolic disorders (1523)
mRNA (222)
Multiple sclerosis (188)
NASH (20)
Neurodegenerative disease (429)
Neuropsychiatric disorders (113)
Neuroscience (3378)
Neurotech (1)
NextGen: Class of 2026 (6773)
Non-profit (4600)
Now hiring (76)
Obesity (726)
Opinion (309)
Ovarian cancer (211)
Pain (254)
Pancreatic cancer (298)
Parkinson's disease (370)
Partnered (34)
Patents (589)
Patient recruitment (662)
Peanut (62)
People (60928)
Pharmaceutical (80)
Pharmacy benefit managers (33)
Phase 1 (22803)
Phase 2 (31993)
Phase 3 (23622)
Pipeline (8051)
Policy (325)
Postmarket research (2605)
Preclinical (9783)
Press Release (67)
Prostate cancer (300)
Psychedelics (62)
Radiopharmaceuticals (340)
Rare diseases (1106)
Real estate (6076)
Recruiting (71)
Regulatory (25815)
Reports (55)
Research institute (2511)
Resumes & cover letters (355)
Rett syndrome (36)
RNA editing (25)
RSV (88)
Schizophrenia (184)
Series A (298)
Series B (219)
Service/supplier (11)
Sickle cell disease (118)
Special edition (27)
Spinal muscular atrophy (170)
Sponsored (48)
Startups (3828)
State (2)
Stomach cancer (19)
Supply chain (129)
Tariffs (88)
The Weekly (93)
Vaccines (1115)
Venture capital (112)
Weight loss (474)
Women's health (123)
Worklife (21)
Date
Today (54)
Last 7 days (807)
Last 30 days (2754)
Last 365 days (30962)
2026 (10948)
2025 (31062)
2024 (36288)
2023 (41011)
2022 (52276)
2021 (56760)
2020 (54918)
2019 (47415)
2018 (35693)
2017 (33022)
2016 (32345)
2015 (38395)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (758)
Alabama (97)
Alaska (7)
Arizona (353)
Arkansas (16)
Asia (41096)
Australia (6846)
California (13073)
Canada (3703)
China (1351)
Colorado (560)
Connecticut (576)
Delaware (395)
Europe (90375)
Florida (1939)
Georgia (418)
Hawaii (3)
Idaho (62)
Illinois (1051)
India (89)
Indiana (591)
Iowa (25)
Japan (525)
Kansas (133)
Kentucky (52)
Louisiana (40)
Maine (75)
Maryland (1570)
Massachusetts (9435)
Michigan (358)
Minnesota (710)
Mississippi (6)
Missouri (145)
Montana (35)
Nebraska (29)
Nevada (138)
New Hampshire (89)
New Jersey (3466)
New Mexico (31)
New York (3412)
North Carolina (1715)
North Dakota (9)
Northern California (6498)
Ohio (385)
Oklahoma (23)
Oregon (44)
Pennsylvania (2613)
Puerto Rico (28)
Rhode Island (51)
South America (1126)
South Carolina (85)
South Dakota (2)
Southern California (5132)
Tennessee (207)
Texas (2061)
United States (46344)
Utah (388)
Vermont (1)
Virginia (314)
Washington D.C. (81)
Washington State (1076)
West Virginia (4)
Wisconsin (129)
Wyoming (2)
745,697 Results for "cytomx therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Astellas Divorces CytomX Despite Positive Phase 1 Data for Antibody Platform
Astellas Pharma and CytomX Therapeutics first partnered up in March 2020. For $80 million upfront, the Japanese pharma gained access to the biotech’s Probody platform to generate masked antibody therapies for cancer.
March 17, 2026
·
2 min read
·
Tristan Manalac
Press Releases
CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
April 30, 2026
·
2 min read
Press Releases
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
March 16, 2026
·
12 min read
Press Releases
CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
March 16, 2026
·
5 min read
Press Releases
CytomX Therapeutics to Present at Upcoming February 2026 Conferences
February 4, 2026
·
2 min read
Press Releases
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
March 18, 2026
·
5 min read
Press Releases
CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026
March 4, 2026
·
2 min read
Press Releases
CytomX Therapeutics Announces Business Update and Company Milestones for 2026
January 8, 2026
·
8 min read
Press Releases
CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
March 16, 2026
·
12 min read
Press Releases
CytomX Therapeutics to Present at Upcoming December 2025 Investor Conferences
November 26, 2025
·
2 min read
1 of 74,570
Next
